Lyell Immunopharma Inc.

11/08/2024 | Press release | Archived content

SITC 2024: LYL797 Reprogrammed ROR-1 CAR T cells Demonstrate Limited Exhaustion, Maintenance of Stemness and Tumor Infiltration with Evidence of Tumor Lysis in Patients with[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.